• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Clair J. Beard, MD


  • Mahal BA, Ziehr DR, Aizer AA, Hyatt AS, Lago-Hernandez C, Choueiri TK, Elfiky AA, Hu JC, Sweeney CJ, Beard CJ, D'Amico AV, Martin NE, Kim SP, Lathan CS, Trinh QD, Nguyen PL.Racial disparities in an aging population: The relationship between age and race in the management of African American men with high-risk prostate cancer.Journal Of Geriatric Oncology. 2014 May 23.
  • Mahal BA, Ziehr DR, Hyatt AS, Neubauer-Sugar EH, O'Farrell DA, O'Leary MP, Steele GS, Niedermayr TR, Beard CJ, Martin NE, Orio PF, D'Amico AV, Devlin PM, Nguyen PL.Use of a rectal spacer with low-dose-rate brachytherapy for treatment of prostate cancer in previously irradiated patients: Initial experience and short-term results.Brachytherapy. 2014 May 28.
  • Mahal BA, Aizer AA, Ziehr DR, Hyatt AS, Choueiri TK, Hu JC, Hoffman KE, Sweeney CJ, Beard CJ, D'Amico AV, Martin NE, Kim SP, Trinh QD, Nguyen PL.Racial Disparities in Prostate Cancer-Specific Mortality in Men With Low-Risk Prostate Cancer.Clin Genitourin Cancer. 2014 May 9.
  • Mahal BA, Ziehr DR, Aizer AA, Hyatt AS, Sammon JD, Schmid M, Choueiri TK, Hu JC, Sweeney CJ, Beard CJ, D׳Amico AV, Martin NE, Lathan C, Kim SP, Trinh QD, Nguyen PL.Getting back to equal: The influence of insurance status on racial disparities in the treatment of African American men with high-risk prostate cancer.Urol Oncol. 2014 May 17.
  • Fennessy FM, McKay RR, Beard CJ, Taplin ME, Tempany CM.Dynamic contrast-enhanced magnetic resonance imaging in prostate cancer clinical trials: potential roles and possible pitfalls.Transl Oncol. 2014 Feb;7(1):120-9.
  • Seible DM, Gu X, Hyatt AS, Beard CJ, Choueiri TK, Efstathiou JA, Miyamoto DT, Mitin T, Martin NE, Sweeney CJ, Trinh QD, Beckman JA, Basaria S, Nguyen PL.Weight Gain on Androgen Deprivation Therapy: Which Patients Are at Highest Risk?.Urology. 2014 Apr 8.
  • Martin NE, Chen MH, Beard CJ, Nguyen PL, Loffredo MJ, Renshaw AA, Kantoff PW, D'Amico AV.Natural history of untreated prostate specific antigen radiorecurrent prostate cancer in men with favorable prognostic indicators.Prostate Cancer. 2014;2014:912943.
  • Travis LB, Fossa SD, Sesso HD, Frisina RD, Herrmann DN, Beard CJ, Feldman DR, Pagliaro LC, Miller RC, Vaughn DJ, Einhorn LH, Cox NJ, Dolan ME, .Chemotherapy-Induced Peripheral Neurotoxicity and Ototoxicity: New Paradigms for Translational Genomics.Journal of the National Cancer Institute. 2014 Mar 12.
  • Kovtun KA, Wolfsberger L, Niedermayr T, Sugar EN, Graham PL, Murciano-Goroff Y, Beard C, D'Amico AV, Martin NE, Orio PF, Nguyen PL.Dosimetric quality and evolution of edema after low-dose-rate brachytherapy for small prostates: implications for the use of newer isotopes.Brachytherapy.;13(2):152-6.
  • Aizer AA, Paly JJ, Zietman AL, Nguyen PL, Beard CJ, Rao SK, Kaplan ID, Niemierko A, Hirsch MS, Wu CL, Olumi AF, Michaelson MD, D'Amico AV, Efstathiou JA.Models of care and NCCN guideline adherence in very-low-risk prostate cancer.J Natl Compr Canc Netw. 2013 Nov;11(11):1364-72.
  • Parekh A, Chen MH, D'Amico AV, Dosoretz DE, Ross R, Salenius S, Graham PL, Beckman JA, Beard CJ, Choueiri TK, Ennis RD, Hoffman KE, Hu JC, Ma J, Martin NE, Nguyen PL.Identification of comorbidities that place men at highest risk of death from androgen deprivation therapy before brachytherapy for prostate cancer.Brachytherapy. 2013 May 4.
  • Beard CJ, Travis LB, Chen MH, Arvold ND, Nguyen PL, Martin NE, Kuban DA, Ng AK, Hoffman KE.Outcomes in stage I testicular seminoma: A population-based study of 9193 patients.Cancer. 2013 Apr 30.
  • Paly JJ, Efstathiou JA, Hedgire SS, Chung PW, O'Malley M, Shah A, Bekelman JE, Harisinghani M, Shipley WU, Zietman AL, Beard C.Mapping patterns of nodal metastases in seminoma: rethinking radiotherapy fields.Radiother Oncol. 2013 Jan;106(1):64-8.
  • Nguyen PL, Devlin PM, Beard CJ, Orio PF, O'Leary MP, Wolfsberger LD, O'Farrell DA, Sweeney CM, Hadaschik BA, Hohenfellner M, Hatiboglu G.High-dose-rate brachytherapy for prostate cancer in a previously radiated patient with polyethylene glycol hydrogel spacing to reduce rectal dose: case report and review of the literature.Brachytherapy.;12(1):77-83.
  • Martin NE, Chen MH, Nguyen PL, Beard CJ, Loffredo MJ, Kantoff PW, D'Amico AV.Biopsy Gleason score and the duration of testosterone suppression among men treated with external beam radiation and 6 months of combined androgen blockade.BJU Int. 2012 Nov;110(9):1252-6.
  • Nguyen PL, Chen MH, Zhang Y, Tempany CM, Cormack RA, Beard CJ, Hurwitz MD, Suh WW, D'Amico AV.Updated results of magnetic resonance imaging guided partial prostate brachytherapy for favorable risk prostate cancer: implications for focal therapy.J Urol. 2012 Oct;188(4):1151-6.
  • Aizer AA, Paly JJ, Zietman AL, Nguyen PL, Beard CJ, Rao SK, Kaplan ID, Niemierko A, Hirsch MS, Wu CL, Olumi AF, Michaelson MD, D'Amico AV, Efstathiou JA.Multidisciplinary care and pursuit of active surveillance in low-risk prostate cancer.J Clin Oncol. 2012 Sep 1;30(25):3071-6.
  • Nguyen PL, Chen MH, Goldhaber SZ, Martin NE, Beard CJ, Dosoretz DE, Katin MJ, Ross R, Salenius SA, D'Amico AV.Coronary revascularization and mortality in men with congestive heart failure or prior myocardial infarction who receive androgen deprivation.Cancer. 2011 Jan 15;117(2):406-13.
  • Nguyen PL, Chen MH, Beard CJ, Suh WW, Renshaw AA, Loffredo M, McMahon E, Kantoff PW, D'Amico AV.Radiation With or Without 6 Months of Androgen Suppression Therapy in Intermediate- and High-Risk Clinically Localized Prostate Cancer: A Postrandomization Analysis by Risk Group.Int J Radiat Oncol Biol Phys. 2010 Jul 15;77(4):1046-52.
  • Nguyen PL, Chen MH, Choueiri TK, Hoffman KE, Hu JC, Martin NE, Beard CJ, Dosoretz DE, Moran BJ, Katin MJ, Braccioforte MH, Ross R, Salenius SA, Kantoff PW, D'Amico AV.Risk of All-Cause and Prostate Cancer-Specific Mortality After Brachytherapy in Men with Small Prostate Size.Int J Radiat Oncol Biol Phys. 2010 Jun 2.
  • Nguyen PL, Chen MH, Beard CJ, Suh WW, Choueiri TK, Efstathiou JA, Hoffman KE, Loffredo M, Kantoff PW, D'Amico AV.Comorbidity, body mass index, and age and the risk of nonprostate-cancer-specific mortality after a postradiation prostate-specific antigen recurrence.Cancer. 2010 Feb 1;116(3):610-5.
  • Lin NU, Kasparian E, Morganstern DE, Beard C.Geographic distribution of lapatinib-induced skin rash: sparing of abdominal skin persists in the transverse rectus abdominis myocutaneous flap.J Clin Oncol. 2009 Dec 1;27(34):e218-9.
  • Hoffman KE,Chen MH,Punglia RS,Beard CJ,D'Amico AV.Influence of year of diagnosis, patient age, and sociodemographic status on recommending adjuvant radiation treatment for stage I testicular seminoma.J Clin Oncol. 2008 Aug 20;26(24):3937-42.
  • Sommers BD,Beard CJ,D'Amico AV,Kaplan I,Richie JP,Zeckhauser RJ.Predictors of patient preferences and treatment choices for localized prostate cancer.Cancer. 2008 Oct 15;113(8):2058-67.
  • Hanna J, Markoulaki S, Schorderet P, Carey BW, Beard C, Wernig M, Creyghton MP, Steine EJ, Cassady JP, Foreman R, Lengner CJ, Dausman JA, Jaenisch R.Direct reprogramming of terminally differentiated mature B lymphocytes to pluripotency.Cell. 2008 Apr 18;133(2):250-64.
  • Albert M, Song JS, Schultz D, Cormack RA, Tempany CM, Haker S, Devlin PM, Beard C, Hurwitz MD, Suh WW, Jolesz F, D'Amico AV.Defining the rectal dose constraint for permanent radioactive seed implantation of the prostate.Urol Oncol. 2008 Mar-Apr;26(2):147-52. Review.
  • Sommers BD, Beard CJ, D'Amico AV, Dahl D, Kaplan I, Richie JP, Zeckhauser RJ.Decision analysis using individual patient preferences to determine optimal treatment for localized prostate cancer.Cancer. 2007 Nov 15;110(10):2210-7.
  • Pomerantz M, Manola J, Taplin ME, Bubley G, Inman M, Lowell J, Beard C, Kantoff PW, Oh WK.Phase II study of low dose and high dose conjugated estrogen for androgen independent prostate cancer.J Urol. 2007 Jun;177(6):2146-50.
  • Nakabayashi M, Beard C, Kelly SM, Carr-Locke DL, Oh WK.Treatment of a radiation-induced rectal ulcer with hyperbaric oxygen therapy in a man with prostate cancer.Urol Oncol. 2006 Nov-Dec;24(6):503-8.
  • Beard C, Schultz D, Loffredo M, Cote K, Renshaw AA, Hurwitz MD, D'Amico AV.Perineural invasion associated with increased cancer-specific mortality after external beam radiation therapy for men with low- and intermediate-risk prostate cancer.Int J Radiat Oncol Biol Phys. 2006 Oct 1;66(2):403-7.
  • D'Amico AV, Manola J, McMahon E, Loffredo M, Lopes L, Ching J, Albert M, Hurwitz M, Suh WW, Vivenzio TA, Beard C.A prospective evaluation of rectal bleeding after dose-escalated three-dimensional conformal radiation therapy using an intrarectal balloon for prostate gland localization and immobilization.Urology. 2006 Apr;67(4):780-4.
  • Beard C, Chen MH, Cote K, Loffredo M, Renshaw A, Hurwitz M, D'Amico AV.Pretreatment predictors of posttreatment PSA doubling times for patients undergoing three-dimensional conformal radiotherapy for clinically localized prostate cancer.Urology. 2005 Nov;66(5):1020-3.
  • Tsai HK, Manola J, Abner A, Talcott JA, D'Amico AV, Beard C.Patient-reported acute gastrointestinal toxicity in men receiving 3-dimensional conformal radiation therapy for prostate cancer with or without neoadjuvant androgen suppression therapy.Urol Oncol. 2005 Jul-Aug;23(4):230-7.
  • Beard CJ.The risk of bladder, bowel, and sexual dysfunction after radiation therapy: what the data tell us and how we can use it to counsel our patients.Cancer J. 2005 Mar-Apr;11(2):106-9.
  • Woel R, Beard C, Chen MH, Hurwitz M, Loffredo M, McMahon E, Ching J, Lopes L, D'Amico AV.Acute gastrointestinal, genitourinary, and dermatological toxicity during dose-escalated 3D-conformal radiation therapy (3DCRT) using an intrarectal balloon for prostate gland localization and immobilization.Int J Radiat Oncol Biol Phys. 2005 Jun 1;62(2):392-6.
  • Landis DM, Schultz D, Cormack R, Tempany C, Beard C, Hurwitz M, O'Leary M, Albert M, Valentine K, D'Amico AV.Acute urinary retention after magnetic resonance image-guided prostate brachytherapy with and without neoadjuvant external beam radiotherapy.Urology. 2005 Apr;65(4):750-4.
  • Letai A, Sorcinelli MD, Beard C, Korsmeyer SJ.Antiapoptotic BCL-2 is required for maintenance of a model leukemia.Cancer Cell. 2004 Sep;6(3):241-9.
  • D'Amico AV, Renshaw AA, Cote K, Hurwitz M, Beard C, Loffredo M, Chen MH.Impact of the percentage of positive prostate cores on prostate cancer-specific mortality for patients with low or favorable intermediate-risk disease.J Clin Oncol. 2004 Sep 15;22(18):3726-32.
  • Beard CJ, Chen MH, Cote K, Loffredo M, Renshaw AA, Hurwitz M, D'Amico AV.Perineural invasion is associated with increased relapse after external beam radiotherapy for men with low-risk prostate cancer and may be a marker for occult, high-grade cancer.Int J Radiat Oncol Biol Phys. 2004 Jan 1;58(1):19-24.
  • Talcott JA, Manola J, Clark JA, Kaplan I, Beard CJ, Mitchell SP, Chen RC, O'Leary MP, Kantoff PW, D'Amico AV.Time course and predictors of symptoms after primary prostate cancer therapy.J Clin Oncol. 2003 Nov 1;21(21):3979-86.
  • Hurwitz MD, Schnieder L, Manola J, Beard CJ, Kaplan ID, D'Amico AV.Lack of radiation dose response for patients with low-risk clinically localized prostate cancer: a retrospective analysis.Int J Radiat Oncol Biol Phys. 2002 Aug 1;53(5):1106-10.
  • Killoran JH, Baldini EH, Beard CJ, Chin L.A technique for optimization of digitally reconstructed radiographs of the chest in virtual simulation.Int J Radiat Oncol Biol Phys. 2001 Jan 1;49(1):231-9.
  • D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Silver B, Henry L, Hurwitz M, Kaplan I, Beard CJ, Tomaszewski JE, Renshaw AA, Wein A, Richie JP.Clinical utility of percent-positive prostate biopsies in predicting biochemical outcome after radical prostatectomy or external-beam radiation therapy for patients with clinically localized prostate cancer.Mol Urol. 2000 Fall;4(3):171-5;discussion 177.
  • D'Amico AV, Schultz D, Loffredo M, Dugal R, Hurwitz M, Kaplan I, Beard CJ, Renshaw AA, Kantoff PW.Biochemical outcome following external beam radiation therapy with or without androgen suppression therapy for clinically localized prostate cancer.JAMA. 2000 Sep 13;284(10):1280-3.
  • D'Amico AV, Whittington R, Malkowicz SB, Fondurulia J, Chen MH, Kaplan I, Beard CJ, Tomaszewski JE, Renshaw AA, Wein A, Coleman CN.Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer.J Clin Oncol. 1999 Jan;17(1):168-72.
  • D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, Tomaszewski JE, Renshaw AA, Kaplan I, Beard CJ, Wein A.Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.JAMA. 1998 Sep 16;280(11):969-74.
  • D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Kaplan I, Beard CJ, Tomaszewski JE, Renshaw AA, Loughlin KR, Richie JP, Wein A.Calculated prostate cancer volume greater than 4.0 cm3 identifies patients with localized prostate cancer who have a poor prognosis following radical prostatectomy or external-beam radiation therapy.J Clin Oncol. 1998 Sep;16(9):3094-100.
  • Beard CJ, Lamb C, Buswell L, Schneider L, Propert KJ, Gladstone D, D'Amico A, Kaplan I.Radiation-associated morbidity in patients undergoing small-field external beam irradiation for prostate cancer.Int J Radiat Oncol Biol Phys. 1998 May 1;41(2):257-62.